Stemcyte-ky is leveraging its US FDA Biologics License Application (BLA) to solidify its commercial layout in cell therapy and regenerative medicine, becoming one of the few Taiwanese firms to surmount high international regulatory barriers. Recently, the Institute for Biotechnology and Medicine Industry (IBMI) organized a cross-sector visit to examine the company’s R&D, manufacturing quality systems, clinical applications, and international expansion.

CEO Dr. Tong-Young Lee pointed out that Stemcyte-ky’s core strength lies in umbilical cord blood cells. Its product, REGENECYTER, has received US FDA BLA approval—the first and currently only cell therapy company in Taiwan to achieve this status. This licensure validates the company's institutional capabilities in "Consistency, Traceability, Release, and Scalability," placing it at the highest tier of global regulatory competition.

Key Strategic Assets:

• Dual Taiwan-US Core: The group operates a 1,300-ping cGMP cell manufacturing facility in the US, which successfully passed FDA on-site inspections. In Taiwan, it operates the Nangang R&D Center, an MOHW-approved organ bank in Linkou, and a GTP (Good Tissue Practice) cell preparation plant in the Central Taiwan Science Park (CTSP).
• Clinical Reach: In the US, REGENECYTER can be applied to nearly 80 diseases, including cancers, hematological, immunological, and metabolic disorders—over half of which are orphan diseases.
• Affordable Regenerative Medicine: Stemcyte-ky has pioneered a "Public Bank Guarantee Service" with a subscription-based model. In November, it partnered with Taishin Life Insurance to integrate insurance applications, enhancing the accessibility of cord blood treatments.

Resource: FDA藥證＋cGMP製造雙引擎 永笙-ky卡位全球再生醫療供應鏈